RE:Next Gen antibodies seeking to mimic Pelareorep + ICI actionI would further propose that this development is another reason why ONCY is worth north of US$ 8 Billion, since it is becoming increasingly evident that Big Pharma is seeking multifunctional assets like ONCY's pelareorep that can address the complex interactions between the tumor and the TME - both by engaging the innate / adaptive immune system and modulating the TME in advance of immune checkpoint inhibition, for the effective treatment of various cancers.